Vitreous tamponades are widely used in vitrectomy procedures worldwide as a vital element in healing process of vitreoretinal disorders. Vitreous tamponades have evolved only to a small extent since the past few decades in ophthalmological procedures. Instead vitrectomy procedures have evolved to a great extent with the inclusion of various instrumental advancements. These instrumental advancements have further increased the effectiveness of vitreous tamponades in terms of their applicability and healing rate. Vitreous tamponades are generally classified into gaseous tamponades and liquid tamponades. Gaseous tamponades are often used in dilution with sterile air and are highly effective for treating small retinal tears. Gaseous tamponades are also highly effective in terms of low toxicity and ease of application. In addition, gaseous tamponades have lower emulsification risk and require fewer revisits. Liquid tamponades on the other hand are effective for larger tears. They however have lower risk of expansion due to pressure changes in the atmosphere, thereby rendering them safe for air travel. Overall vitreous tamponades show great potential for treating majority of the severe vitreoretinal disorders that require surgical intervention. Transparency Market Research, a leading U.S. based market research firm, analyzes the global market for vitreous tamponades and predicts a compounded annual growth rate of 2.5% for the period 2014 to 2020.
Browse the full Vitreous Tamponades Market (Tamponades Types: Gaseous Tamponades and Liquid Tamponades [Silicone Oil, Perfluorocarbons]) – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020 report at http://www.transparencymarketresearch.com/vitreous-tamponades-market.html
The global vitreous tamponades industry is broadly categorized on the basis of product types and geographies. The vitreous tamponades product category is further segmented into gaseous tamponades and liquid tamponades. Among these sub segments, the market for liquid tamponades exhibits the largest share in 2013, whereas gaseous tamponades show the highest growth rate during the forecast period 2014 – 2020. The high prevalence of larger retina tear, and ophthalmologist preference for liquid tamponades in major economies in the world have lead to the growth of liquid tamponade segment in the world. The gaseous tamponade segment is however expected to lead the market in terms of growth rate. Gaseous tamponade is the most preferred segment in the North American region which is supported by low incidence of diabetic retinopathy in developed nations.
Geographically, in 2013 the global vitreous tamponades market is lead by the North America, followed by Europe. The dominance of this region was majorly due to rising diabetic population, increasing surgeons coupled with high cost of vitreoretinal surgery equipment. The Asia-Pacific market is forecast to grow at the highest growth rate during the forecast period of 2014 to 2020. The contributing factors for Asia Pacific growth include: large geriatric population, low penetration of healthcare facilities, favorable & supportive government policies, low technology cost & other overheads, adoption of novel technologies, growing awareness of basic healthcare, and the fact that Asia is the largest and fastest growing population in the world. In addition, presence of large number of tamponade manufacturers offering products readily and at an affordable cost further propels the growth of vitreous tamponades in Asia-Pacific.
Request A Sample Of This Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4233
The leading players in this market include: Alcon, Inc., Fluoron GmbH and Valeant Pharmaceuticals International, Inc. (parent of Bausch + Lomb), to name a few. Among these Alcon, Inc. was found to have the largest global presence, offering a wide range of vitreous tamponade products globally. The other companies include: Carl Zeiss Meditec AG, Dutch Ophthalmic Research Center B.V., Fluoron GmbH, Croma Pharma AG, and AL.CHI.MI.A Srl, to name a few.
No comments:
Post a Comment